Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03917095

The Safety and Efficacy of TET Enema in the Treatment of UC

Ulcerative Colitis Chronic Moderate Clinical Trial

Official title:
Mesalazine and Compound Glutamin Enema for the Treatment of Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing: A Multicenter, Randomized, Controlled Trail

Clinical Trial Summary

Colonic Transendoscopic enteral Tubing(TET) is a novel, safe, convenient, and reliable procedure for Fecal Microbiota Transplantation(FMT).This clinical trail aims to evaluate the efficacy and safety of Mesalazine and Compound Glutamine enema in the treatment of Ulcerative Colitis through Colonic TET.

Clinical Trial Description

Enema is a conventional treatment for Ulcerative Colitis(UC). Mesalazine is suitable for the patients with mild to moderate UC.But for the UC with extending lesions, the conventional anema with Mesalazine or other medicine can not very effective.Colonic Transendoscopic enteral Tubing(TET) is a novel, safe, convenient, and reliable procedure for Fecal Microbiota Transplantation(FMT).Compared with the conventional enema, which is only used for local administration, the Colonic TET enema can achieve total colonic administration.This study aims to evaluate the efficacy and safety of Colonic TET for UC.Patients in this study will be divided into 5 groups according to certain criteria: the Mesalazine conventional enema group, the Mesalazine TET enema group, the Compound Glutamine conventional enema group, the Compound Glutamine TET enema group, the Mesalazine and Compound Glutamine TET enema group.Each group was given enema for 7 days.The primary outcome measure was the clinical remission efficacy rate in each group. The secondary outcome measure was the safety of TET. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03917095
Study type Interventional
Source The Second Hospital of Nanjing Medical University
Contact Faming Zhang, MD,PhD
Phone 086-25-58509883
Email fzhang@njmu.edu.cn
Status Recruiting
Phase N/A
Start date May 15, 2019
Completion date June 30, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT04102852 - Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients Phase 1/Phase 2
Completed NCT04353791 - Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis Phase 1/Phase 2
Recruiting NCT06311123 - Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis
Recruiting NCT05735665 - Comparison Between Bowel Ultrasound-based Treat to Target Versus Routine Treat to Target Strategies in Ulcerative Colitis N/A
Completed NCT03565939 - Probiotic Treatment of Ulcerative Colitis With Trichuris Suis Ova (TSO) Phase 2
Terminated NCT03923478 - ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis Phase 1
Not yet recruiting NCT05912712 - Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum for the Topical Treatment of Rectal Mucosal Ulcers Phase 1
Recruiting NCT05666960 - R-3750 in Patients With Mild to Moderate Ulcerative Colitis Phase 1
Recruiting NCT05194007 - Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease Phase 2/Phase 3
Recruiting NCT05791487 - Combination of Diet and Oral Budesonide for Ulcerative Colitis N/A
Recruiting NCT03716388 - Fecal Microbiota Therapy Vs 5-aminosalicylates for Induction of Remission in Newly Diagnosed Mild-moderately Active UC Phase 3
Completed NCT04504383 - PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC) Phase 2
Not yet recruiting NCT06420492 - Study of Novel Therapeutics for Acute Remedy of Colitis Phase 2